PPT-MDR and XDR TB

Bruce A Bush MD Regional Tuberculosis Consultant Pennsylvania Department of Health Senior Vice President for Medical Affairs Indiana Regional Medical Center Disclosures I do not have any financial arrangements or affiliations with a commercial entity. Scott K. . Heysell. MD, MPH. (no disclosures). Why do we need new drugs/ regimens?. ▪Isoniazid and pyrazinamide remain some of the most . toxic. antibiotics prescribed for infectious disease . -. We would like to remind you that this material is the property of the author.. It is provided to you by the ERS for your personal use only, as submitted by the author. . 2012 by the author. Evolution of TB control and elimination strategies. Bruce A. Bush, M.D.. Regional Tuberculosis Consultant. Pennsylvania Department of Health. Senior Vice President for Medical Affairs. Indiana Regional Medical Center. Disclosures. I do not have any financial arrangements or affiliations with a commercial entity.. We would like to remind you that this material is the property of the author.. It is provided to you by the ERS for your personal use only, as submitted by the author. . 2012 by the author. Evidence provided by recent metanalyses on treatment: . F. uture . of TB . Therapy. Putting science to work for better, faster TB cures. Achieving maximum impact will require:. Short, simple regimens that are adopted, available and affordable.. Ideally, a universal regimen consisting of all novel drugs that is effective in all people with active TB. . Mycobacterial . Disease. . Increasing . Role for Surgery, Relearning Old Lessons. John D. Mitchell, M.D.. Professor and Chief. Section of General Thoracic Surgery. Davis Endowed Chair in Thoracic Surgery. Disseminate recommendations to each Division Officer/LCPO. W/C Supervisor identify personnel meeting criteria. W/C personnel schedule exam with Occupational Health clinic or supporting MDR. W/C personnel go to exam appointment(s) and inform Div chain of command when complete. Naira Dekhil. 1. , . Besma. Mhenni. 1. , Raja Haltiti. 2. , and . Helmi. Mardassi. 1. . (speaker).  . 1. Unit of Typing & Genetics of . Mycobacteria. , . Institut. Pasteur de Tunis, . Tunisia. ries 14 61 contributed data on 17690 isolates whichThese drugs are more costly toxic and less effective thanfirst-line drugs used for routine treatment of TB with other diseases resistance to TB drugs tuberculosis in high-burden countries. Kathrin . Zürcher. , Marie . Ballif. , Lukas . Fenner. , Sonia . Borrell. , Peter M. Keller, Joachim . Gnokoro. , Olivier Marcy, Marcel . Yotebieng. , . Lameck. Echols RM, Tomayko JF, Dudley MN, Dane A. Progress in the fight against multidrug-resistant bacteria 2005-2016: Modern non-inferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. . Murase Y, Maeda S, Yamada H, Ohkado A, Chikamatsu K, Mizuno K, et al. Clonal Expansion of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, Japan. Emerg Infect Dis. 2010;16(6):948-954. https://doi.org/10.3201/eid1606.091844. Álvarez-Narváez S, Giguère S, Cohen N, Slovis N, Vázquez-Boland JA. Spread of Multidrug-Resistant Rhodococcus equi, United States. Emerg Infect Dis. 2021;27(2):529-537. https://doi.org/10.3201/eid2702.203030. Programmatic Management of Drug Resistant TB (PMDT) Officer – The Union. 1. MDR-TB Epidemiology. MDR-TB is a public health crisis and a global health security risk carrying grave consequences for those affected..